Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
September 05, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
August 30, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
August 29, 2023 06:58 ET
|
Apellis Pharmaceuticals, Inc.
Maximizing global leadership of SYFOVRE in geographic atrophy (GA) Streamlining the EMPAVELI business and prioritizing development of systemic pegcetacoplan in IC-MPGN/C3G Focusing research...
Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
August 22, 2023 16:43 ET
|
Apellis Pharmaceuticals, Inc.
Internal structural variations were identified in the 19-gauge filter needle included in certain injection kits; Apellis recommends use of kits with the 18-gauge filter needle, which are already in...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
July 31, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
Generated total U.S. net product revenues of $89.6 million, including $67.3 million for SYFOVRE® (pegcetacoplan injection) and $22.3 million for EMPAVELI® (pegcetacoplan)SYFOVRE reduced nonsubfoveal...
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
July 30, 2023 13:00 ET
|
Apellis Pharmaceuticals, Inc.
SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected sham in the GALE long-term extension study Safety profile of SYFOVRE in GALE was consistent with...
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
July 29, 2023 14:52 ET
|
Apellis Pharmaceuticals, Inc.
No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitisConfirmed seven total events of non-occlusive/occlusive retinal vasculitis since launch; more...
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
July 24, 2023 09:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 10, 2023 07:00 ET
|
Apellis Pharmaceuticals, Inc.
New 30-month data from the GALE long-term extension study of SYFOVRE® (pegcetacoplan injection) to be presented WALTHAM, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc....